Remove Containment Remove Contract Manufacturing Remove Life Science Remove Sales
article thumbnail

Sartorius Stedim Biotech to acquire Novasep’s chromatography process equipment division

The Pharma Data

Novasep’s division expects to generate sales revenue of approximately 37 million euros in 2020 at double-digit profit margins and employs approximately 100 people, the majority of whom work at its Pompey site in northern France and some in the USA , China and India. . 6,200 people, and earned sales revenue of 1,440.6

article thumbnail

Sartorius to acquire Novasep’s chromatography process equipment division

The Pharma Data

6, 2021 /PRNewswire/ — The life science company Sartorius today announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep. . In fiscal 2019, the company earned sales revenue of some 1.83 About Sartorius. billion euros.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

INOVIO is also assessing nonclinical efficacy of INO-4800 in several animal challenge models with Public Health England (PHE) and Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia.

DNA 40
article thumbnail

Athersys Announces Three Appointments to Board of Directors

The Pharma Data

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Mr. Shah is a seasoned executive, entrepreneur, and investor with more than 20 years of experience in building life science technology companies. Before that, Ms. Forward-Looking Statements.

article thumbnail

XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact

The Pharma Data

As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. . VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.

Drugs 52
article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

“Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.